SCHEMBL3024075

SCHEMBL3024075

Cc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3ccc(C(C)(C)C)cc3)CC2)n1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.38
GBA1 P04062 2/20 0.38
LMNA P02545 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MAPK1 P28482 1/20 0.34
GLA P06280 1/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34
DNM1L O00429 3/20 0.33
HTR2A P28223 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32
ADRB3 P13945 1/20 0.32
DCTPP1 Q9H773 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020316 0.93 GBA1 (0.35) HSD11B1GBA1LMNAMEN1KMT2A
SCHEMBL3002378 0.91 GBA1 (0.46) GBA1LMNAMEN1KMT2AALDH1A1
SCHEMBL3015354 0.90 HSD11B1 (0.36) HSD11B1GBA1LMNAMEN1KMT2A
SCHEMBL3017650 0.90 GBA1 (0.39) GBA1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3008086 0.89 GBA1 (0.37) HSD11B1GBA1LMNAKMT2AALDH1A1
SCHEMBL3021138 0.89 GBA1 (0.39) GBA1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3012981 0.89 KDM4E (0.41) GBA1LMNAMEN1KMT2AALDH1A1
SCHEMBL3007549 0.88 EDNRA (0.38) HSD11B1GBA1MEN1KMT2AALDH1A1
SCHEMBL3012703 0.88 HTR2A (0.41) HSD11B1GBA1LMNAMEN1KMT2A
SCHEMBL3017247 0.87 GBA1 (0.38) GBA1LMNAMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD11B1 1034/4885GBA1 4/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.